AR076177A1 - MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL - Google Patents

MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL

Info

Publication number
AR076177A1
AR076177A1 ARP100101094A ARP100101094A AR076177A1 AR 076177 A1 AR076177 A1 AR 076177A1 AR P100101094 A ARP100101094 A AR P100101094A AR P100101094 A ARP100101094 A AR P100101094A AR 076177 A1 AR076177 A1 AR 076177A1
Authority
AR
Argentina
Prior art keywords
oral cavity
condition
matrix metalloproteinases
expression
positive control
Prior art date
Application number
ARP100101094A
Other languages
English (en)
Inventor
Virginia Barnes
Harsh M Trivedi
Wei Wang
Tao Xu
Emi Shimizu
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42328354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of AR076177A1 publication Critical patent/AR076177A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Reivindicacion 1: Un método para identificar un compuesto que es util para tratar una enfermedad o condicion de la cavidad oral, caracterizado por que comprende: Obtener una primera muestra gingival, a partir de un mamífero que sufre de una enfermedad o condicion de la cavidad oral; Obtener una segunda muestra gingival de la cavidad oral de dicho mamífero; contactar dicha primera muestra con un compuesto de prueba; contactar dicha segunda muestra con un control positivo, en donde dicho control positivo es un compuesto conocido por regular decrecientemente la expresion de uno o más metaloproteinasas de matriz; Medir la extension a la cual la expresion de uno o más de dicha metaloproteinasas de matriz que es regulada decrecientemente por dicho compuesto de prueba; Medir la extension a la cual la expresion de uno o más de dicha metaloproteinasas de matriz es regulada decrecientemente, por dicho control positivo; y comparar la extension a la cual la expresion de una o más de dicha metaloproteinasas de matriz es regulada decrecientemente, por dicho compuesto de prueba, con la medida con la que la expresion de uno o más de dichas metaloproteinasas de matriz es regulada decrecientemente por dicho control positivo; en donde un compuesto de prueba que regula decrecientemente la expresion de uno o más de dichas metaloproteinasas de matriz a una medida igual o mayor que la de dicho control positivo, es un compuesto util en tratar una enfermedad o condicion de una cavidad oral. Reivindicacion 2: El método de la reivindicacion 1, caracterizado por que dicha una o más metaloproteinasas de matriz son seleccionadas del grupo que consiste de: MMP-8, MMP-9, y MMP-13. Reivindicacion 4: El método de cualquiera de las reivindicaciones precedentes, caracterizado por que dicha enfermedad o condicion de la cavidad oral, es una gingivitis o periodontitis. Reivindicacion 6: El método de cualquiera de las reivindicaciones precedentes, caracterizado por que el control positivo es triclosán.
ARP100101094A 2009-04-01 2010-03-31 MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL AR076177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16568509P 2009-04-01 2009-04-01

Publications (1)

Publication Number Publication Date
AR076177A1 true AR076177A1 (es) 2011-05-26

Family

ID=42328354

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101094A AR076177A1 (es) 2009-04-01 2010-03-31 MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL

Country Status (20)

Country Link
US (1) US8637266B2 (es)
EP (1) EP2414838B1 (es)
JP (1) JP5330596B2 (es)
CN (1) CN102365550B (es)
AR (1) AR076177A1 (es)
AU (1) AU2010232590B2 (es)
BR (1) BRPI1013185A2 (es)
CA (1) CA2757317C (es)
CO (1) CO6420374A2 (es)
DK (1) DK2414838T3 (es)
ES (1) ES2432864T3 (es)
HK (1) HK1167272A1 (es)
MX (1) MX2011008438A (es)
MY (1) MY158406A (es)
PL (1) PL2414838T3 (es)
RU (1) RU2524629C2 (es)
SG (1) SG173487A1 (es)
TW (1) TWI405565B (es)
WO (1) WO2010115031A1 (es)
ZA (1) ZA201106054B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101745067B1 (ko) * 2014-12-31 2017-06-12 서울대학교산학협력단 치주질환 예측 시스템 및 이를 이용한 치주질환 예측 방법
KR102098624B1 (ko) * 2019-09-20 2020-04-08 서울대학교산학협력단 타액 mmp-9 및 il-8를 이용한 치주염 예측 시스템 및 이를 이용한 치주염 예측 방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538230A (en) 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US4358437A (en) 1978-11-29 1982-11-09 Beecham Group Limited Compositions
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US5288480A (en) 1987-01-30 1994-02-22 Colgate-Palmolive Co. Antiplaque antibacterial oral composition
US5032386A (en) 1988-12-29 1991-07-16 Colgate-Palmolive Company Antiplaque antibacterial oral composition
GB9117140D0 (en) 1991-08-08 1991-09-25 Unilever Plc Treatment of periodontitis
DE4226043A1 (de) 1992-08-06 1994-02-10 Haarmann & Reimer Gmbh Mittel mit physiologischem Kühleffekt und für diese Mittel geeignete wirksame Verbindungen
US5756361A (en) * 1992-12-17 1998-05-26 Metra Biosystems, Inc. Screening method for periodontal disease
US5840302A (en) 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
FI98961C (fi) * 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5578295A (en) 1995-04-28 1996-11-26 The Procter & Gamble Company Oral care compositions comprising certain substituted diphenyl ethers
DE59704397D1 (de) 1996-06-12 2001-09-27 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische zubereitungen
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
JP3763075B2 (ja) * 1998-04-24 2006-04-05 サンスター株式会社 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物
FR2794457B1 (fr) 1999-06-01 2001-08-10 Oreal Derives carbonates de retinol, procede de preparation et utilisations
US6165447A (en) * 1999-06-15 2000-12-26 Colgate-Palmolive Company Synergistic antibacterial combination
EP2295968B1 (en) 1999-12-03 2012-09-19 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6500409B1 (en) 2000-05-10 2002-12-31 Colgate Palmolive Company Synergistic antiplaque/antigingivitis oral composition
DE10059584A1 (de) 2000-11-30 2002-06-06 Beiersdorf Ag Kosmetische oder dermatologische getränkte Tücher
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
WO2004014866A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
US7005225B2 (en) 2002-11-12 2006-02-28 Samsung Electronics Company Organosol including amphipathic copolymeric binder having crystalline material, and use of the organosol to make dry tones for electrographic applications
US20040224876A1 (en) 2003-02-14 2004-11-11 Jost-Price Edward Roydon Combination therapy for the treatment of immunoinflammatory disorders
GB2401865A (en) 2003-05-22 2004-11-24 Givaudan Sa Antibacterial and antifungal glycerol monocarbonates
US7202234B2 (en) 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
JP2007519894A (ja) 2003-12-03 2007-07-19 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ 標的としてのカドヘリンの使用
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
JP4662043B2 (ja) * 2004-09-09 2011-03-30 国立大学法人東京農工大学 歯周病発症の評価システム
CN101111288A (zh) * 2004-12-02 2008-01-23 高露洁-棕榄公司 含酚类化合物和抗氧化剂维生素和维生素衍生物的口腔护理组合物
US20060141421A1 (en) 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. System and method for detecting substances related to oral health
WO2006074450A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
JP5024506B2 (ja) * 2005-03-25 2012-09-12 ライオン株式会社 歯周組織破壊の抑制・改善剤及び口腔用組成物
DK1971865T3 (da) 2006-01-10 2013-07-08 Colgate Palmolive Co Fremgangsmåder til modulering af celleoverfladereceptorer til at forebygge eller reducere inflammation
US20080161394A1 (en) 2006-11-23 2008-07-03 Jean-Yves Fouron Cosmetic composition comprising at least one volatile carbonic acid ester
WO2008093072A2 (en) 2007-01-29 2008-08-07 Paul Webb Topical composition against contact dermatitis due to water
WO2009048841A1 (en) 2007-10-09 2009-04-16 Humco Holding Group, Inc. Antifungal treatment of nails
AR076041A1 (es) * 2009-04-01 2011-05-11 Colgate Palmolive Co Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral

Also Published As

Publication number Publication date
BRPI1013185A2 (pt) 2016-04-12
US8637266B2 (en) 2014-01-28
HK1167272A1 (en) 2012-11-23
EP2414838B1 (en) 2013-08-28
MX2011008438A (es) 2011-09-06
EP2414838A1 (en) 2012-02-08
WO2010115031A1 (en) 2010-10-07
US20120107843A1 (en) 2012-05-03
ES2432864T3 (es) 2013-12-05
DK2414838T3 (da) 2013-11-04
ZA201106054B (en) 2014-01-29
CA2757317A1 (en) 2010-10-07
SG173487A1 (en) 2011-09-29
JP2012524884A (ja) 2012-10-18
RU2011144028A (ru) 2013-05-10
AU2010232590B2 (en) 2013-03-07
CA2757317C (en) 2014-03-11
JP5330596B2 (ja) 2013-10-30
CN102365550A (zh) 2012-02-29
RU2524629C2 (ru) 2014-07-27
MY158406A (en) 2016-10-14
TWI405565B (zh) 2013-08-21
AU2010232590A1 (en) 2011-08-18
CO6420374A2 (es) 2012-04-16
PL2414838T3 (pl) 2014-01-31
CN102365550B (zh) 2014-08-13
TW201039812A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
Vemu et al. Severing enzymes amplify microtubule arrays through lattice GTP-tubulin incorporation
Fidelin et al. State-dependent modulation of locomotion by GABAergic spinal sensory neurons
Böhm et al. CSF-contacting neurons regulate locomotion by relaying mechanical stimuli to spinal circuits
Boyd et al. Cortical feedback control of olfactory bulb circuits
Scott et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value
BR112015004881A2 (pt) método para diagnosticar o estado da doença periodontal e kit para diagnosticar o estado da doença periodontal
CO6430490A2 (es) Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral
Rusakov et al. Diversity of astroglial functions alludes to subcellular specialisation
CO6220937A2 (es) Compuestos triciclicos composiciones y procedimientos
NZ628843A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Tatti et al. A population of glomerular glutamatergic neurons controls sensory information transfer in the mouse olfactory bulb
Shen et al. GABAergic control of critical developmental periods for anxiety-and depression-related behavior in mice
AR038106A1 (es) Metodos y sistemas para predecir un puntaje de condicion corporal para mascotas
DK1756571T3 (da) Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
AR076177A1 (es) MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL
BR112015030839A2 (pt) método para remoção de unha artificial, composição de unha artificial, unha artificial, método de formação de unha artificial, e kit da técnica para unha
AR033141A1 (es) Produccion de neuronas tirosina hidroxilasa positivas
BRPI0714563B8 (pt) métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato
Williams et al. Cortical nNOS/NK1 receptor neurons are regulated by cholinergic projections from the basal forebrain
Jefferson et al. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Úbeda et al. Ecology drives intragenomic conflict over menopause
Cason et al. Spatiotemporal analysis of axonal autophagosome–lysosome dynamics reveals limited fusion events and slow maturation
Viais et al. Augmin deficiency in neural stem cells causes p53-dependent apoptosis and aborts brain development
Hutcheson et al. Elastogenesis correlates with pigment production in murine aortic valve leaflets
Ono et al. Glutamate release from astrocyte cell-line GL261 via alterations in the intracellular ion environment

Legal Events

Date Code Title Description
FB Suspension of granting procedure